http://www.cannabisscience.com/news-a-media/63-42709-cannabis-science-inc-reports-on-prospective-life-saving-treatments.html

Cannabis Science Inc. Reports on Prospective Life Saving Treatments for H1N1 Swine
Flu and H5N1 Bird Flu in View of the Current Global Threat

SAN FRANCISCO--(BUSINESS WIRE)--Cannabis Science Inc. (OTCBB: GFON.OB), an
emerging pharmaceutical cannabis company, reported today on the current state of
development of its whole-cannabis lozenge in response to Homeland Security
Administration Secretary Janet Napolitano’s declaration of a public health emergency
to deal with the emerging Swine Flu pandemic. The Company’s non-toxic lozenge has
properties that could alleviate many of the symptoms and harmful effects of the
H5N1 bird flu and H1N1 swine flu viruses, and has offered its assistance to HSA today
in a letter to Secretary Napolitano. The Company has offered to produce up to 1
million doses of its whole-cannabis lozenge, and provide them to HSA for distribution
at cost.

Cannabis Science Inc., President & CEO, Steven W. Kubby said, "We have the
science and preliminary anecdotal results confirming the anti-inflammatory properties
of our new lozenges and indicating they may present an effective and non-toxic
treatment for minimizing the symptoms and harm from influenza infections. Our
lozenges appear to down-regulate the body's excessive inflammatory response to the
influenza virus, which could reduce the deadly consequences of an infection into
something that is more like a common cold. Because of my cancer and diminished
auto-immune functions, even common influenza is a deadly threat, and I’ve had
incredible symptomatic relief with the lozenge.”

Dr. Robert J. Melamede, Director and Chief Science Officer, stated, "The influenza
virus has a unique genetic make up that, in combination with its replicative
machinery, has an extraordinary capacity to mutate. As a result, the high lethality of
some strains can be attributed to the resulting adult respiratory distress syndrome
(ARDS). ARDS is caused by an excessive immune inflammatory response driven by
Tumor Necrosis Factor (TNF) that leads to the death of respiratory epithelial cells and
resulting organ failure. Endocannabinoids are nature’s way of controlling TNF activity.
Existing peer reviewed publications have shown that phytocannabinoids can prevent
this cell death by mimicking the endocannabinoids that nature has selected to
prevent excessive inflammatory immune responses.”

Dr. Melamede, who is also a researcher and past Chairman of the Biology
Department at the University of Colorado Springs (UCCS), cautioned, “Smoked
marijuana will not effectively prevent the excessive inflammatory response, despite
delivering the beneficial pharmacological agents, due to the irritating, pro-
inflammatory nature of smoke. In fact, I believe it will make things worse and should
be avoided by infected individuals."

Mr. Kubby added, “If a swine or bird flu pandemic emerges -- and everyone seems
to think that it is just a matter of when, not if --, there is simply no time for the usual
bureaucratic process. With emergency government approval, we can legally access
the huge supply of medical cannabis available in California to produce millions of life
saving doses within a relatively short period of time.”

Dr. Melamede furthermore stated, "Based upon recent discoveries regarding the role
that endocannabinoid system plays in maintaining human health, we have a unique
solution to the looming threat posed by deadly influenza strains that we believe, if
implemented, could save millions of lives. We will strive for an emergency review of
our cannabis extract-based lozenge because we believe its availability will prevent
many of the deaths associated with the hyper-inflammatory response associated with
known lethal strains of the influenza virus. Current anti-influenza medications have a
demonstrated decreased effectiveness against some of these lethal variants. Mankind
cannot wait for the emergency situation to materialize. We must be proactive in
gaining the necessary governmental approvals to test, and pending the outcome of
our studies, produce our lozenge.”

Mr. Richard Cowan, Director and CFO, who recently spoke in Mexico City to a
conference sponsored by the Mexican Congress, stated, “I believe the Mexican
Congress recognizes that doctors should be able to prescribe medical cannabis. We
are prepared to work with the government of Mexico to produce similar medical
cannabis products to help fight the outbreak there. We look forward to working with
Government officials, including Homeland Security, to help advance our treatments
for these outbreaks in Mexico, Canada, the USA, and around the world.”

About the H5N1 Bird Flu and H1N1 Swine Flu Strains

The H5N1 bird flu currently has 63% lethality. A swine-derived H1N1 strain was
responsible for 20,000,000 influenza associated deaths in 1918 (more than killed by
World War I). The current lethal outbreak of swine flu (H1N1) in Mexico has killed
over 80 people and infected more than 1,400 others. There are 20 confirmed cases in
the United States, with reports of infections in Texas, New York, Ohio, California and
Kansas. Additional reports identify possible cases in New Zealand, Canada, Spain,
France and Israel. The H1N1 Swine flu is a porcine respiratory disease caused by
type A flu viruses. Human cases occur in people who are around pigs, but an
infected person can transmit the disease to another person. Symptoms include a high
fever, body aches, coughing, sore throat and respiratory congestion.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and
development. The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific methodologies to develop,
produce, and commercialize phytocannabinoid-based pharmaceutical products. In
sum, we are dedicated to the creation of cannabis-based medicines, both with and
without psychoactive properties, to treat disease and the symptoms of disease, as
well as for general health maintenance.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A
statement containing works such as "anticipate," "seek," "intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-
looking statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Some or all of the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of competition, and the
Company’s reliance on existing regulations regarding the use and development of
cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking statements.

Cannabis Science Inc.
Steven W. Kubby, President & CEO, 888-889-0888
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

http://www.cannabisscience.com/news-a-media/62-42309-cannabis-compounds-
reduce-multi-drug-resistant-infections.html?9cd70057edd40a214f92d201febf4442=
9a638b8bc9c97f99252aebff538b185f

Cannabis Compounds Reduce Multi-Drug Resistant Infections

SAN FRANCISCO--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: GFON.OB). Dr.
Robert Melamede, PhD., Director and Chief Science Officer, reported to the Board on
the current state of research into the use of natural plant cannabinoids to reduce the
spread of drug-resistant bacteria, including methicillin-resistant Staphyloccus aureus
(MRSA), and the prospects for development of topical whole-cannabis treatments.

According to studies published in the Journal of the American Medical Association and
by the Center for Disease Control in 2007, MRSA is responsible for more than 18,500
hospital-stay related deaths each year, and increased direct healthcare costs of as
much as $9.7 billion.

Dr. Melamede stated, "Research into use of whole cannabis extracts and multi-
cannabinoid compounds has provided the scientific rationale for medical marijuana’s
efficacy in treating some of the most troubling diseases mankind now faces, including
infectious diseases such as the flu and HIV, autoimmune diseases such as ALS (Lou
Gehrig’s Disease), multiple sclerosis, arthritis, and diabetes, neurological conditions
such as Alzheimer's, stroke and brain injury, as well as numerous forms of cancer.
One common element of these diseases is that patients often suffer extended hospital
stays, risking development of various Staphyloccus infections including MRSA. A
topical, whole-cannabis treatment for these infections is a functional complement to
our cannabis extract-based lozenge."

Investigators at Italy's Universita del Piemonte Orientale and Britain's University of
London, School of Pharmacy reported in the Journal of Natural Products that five
cannabinoids - THC, CBD, CBG, CBC, and CBN - "showed potent antibacterial activity"
and "exceptional" antibacterial activity against two epidemic MRSA occurring in UK
hospitals. The authors concluded: "Although the use of cannabinoids as systemic
antibacterial agents awaits rigorous clinical trials, ... their topical application to reduce
skin colonization by MRSA seems promising. … Cannabis sativa … represents an
interesting source of antibacterial agents to address the problem of multidrug
resistance in MRSA and other pathogenic bacteria."

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and
development. The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific methodologies to develop,
produce, and commercialize phytocannabinoid-based pharmaceutical products. In
sum, we are dedicated to the creation of cannabis-based medicines, both with and
without psychoactive properties, to treat disease and the symptoms of disease, as
well as for general health maintenance.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A
statement containing works such as "anticipate," "seek," "intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-
looking statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Some or all of the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of competition, and the
Company's reliance on existing regulations regarding the use and development of
cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking statements.


_______________________________________________
Theharderstuff mailing list
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
http://mail.psychedelic-library.org/mailman/listinfo/theharderstuff